Three biotechs go public as IPO momentum increases

28 January 2025

The biotech sector’s initial public offering (IPO) activity is off to a brisk start in 2025, with Aurion Biotech, Maze Therapeutics, and Metsera filing for initial public offerings, aiming to capitalize on investor interest.

Aurion, which specializes in regenerative therapies to treat corneal endothelial diseases, aims to raise funds to support the development of its lead candidate, AURN001, an allogeneic cell therapy.

The firm is looking to build on the success of its earlier product, Vyznova (neltependocel), which launched commercially in Japan in September 2024. An improved formulation, AURN001 offers better manufacturing scalability and extended shelf life.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK